FNCL 2.5 2013 USB Float (ODTC)
OTC PINK OTC PINK Primary Summary
ODTC Chart
People also search for
FNCL 2.5 2013 USB Float (ODTC) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has FNCL 2.5 2013 USB Float ever had a stock split?
FNCL 2.5 2013 USB Float Profile
| Biotechnology Industry | Healthcare Sector | Kevin C. Tang CEO | OTC PINK Exchange | 676079403 CUSIP |
| US Country | 137 Employees | - Last Dividend | 15 Jan 2025 Last Split | 7 Dec 2017 IPO Date |
Overview
Odonate, Inc. stands as a prominent figure in the pharmaceutical landscape, focusing its efforts on devising treatments specifically targeted at cancer. The company embarked on its journey in 2013, establishing its foundation in New York, New York. Throughout its trajectory, Odonate, Inc. has undergone significant transformations, including a notable change from its original name, Odonate Therapeutics, Inc., to its current denomination in March 2023. This renaming reflects the company's evolving identity and its steadfast commitment to advancing cancer treatment options through innovative pharmaceutical development.
Products and Services
- Tesetaxel
At the heart of Odonate, Inc.'s pipeline is tesetaxel, a pioneering chemotherapeutic agent designed for oral administration, setting it apart from conventional intravenous therapies. Currently in Phase III clinical trials, tesetaxel exhibits the company's progressive strides towards revolutionizing treatment modalities for metastatic breast cancer. This therapeutic endeavor not only highlights the advanced research and development initiatives undertaken by Odonate, Inc. but also signifies the potential for a transformative impact on the treatment landscape for patients grappling with this challenging condition.
